SCHEMBL5776546

SCHEMBL5776546

COC(=O)c1ccc(CN(C)CCO)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4A11 Q02928 2/20 0.57
CYP4F2 P78329 1/20 0.55
LOXL2 Q9Y4K0 1/20 0.53
ALDH1A1 P00352 4/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
KDM4E B2RXH2 2/20 0.50
NPC1 O15118 1/20 0.50
GAA P10253 1/20 0.50
HPGD P15428 1/20 0.50
TSHR P16473 1/20 0.50
MAPK1 P28482 1/20 0.50
HSD17B10 Q99714 1/20 0.50
RAB9A P51151 1/20 0.48
SIGMAR1 Q99720 1/20 0.47
ACHE P22303 2/20 0.47
LMNA P02545 1/20 0.47
BCHE P06276 1/20 0.47
MAPT P10636 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
CA12 O43570 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5775042 0.86 LOXL2 (0.56) CYP4A11CYP4F2LOXL2ALDH1A1SMN1; SMN2
SCHEMBL9825792 0.86 CYP4A11 (0.64) CYP4A11CYP4F2LOXL2ALDH1A1SMN1; SMN2
SCHEMBL7468445 0.85 CYP4A11 (0.58) CYP4A11CYP4F2LOXL2ALDH1A1SMN1; SMN2
SCHEMBL3036189 0.84 PRMT1 (0.52) CYP4A11CYP4F2LOXL2ALDH1A1SMN1; SMN2
SCHEMBL23423391 0.83 LOXL2 (0.56) CYP4A11CYP4F2LOXL2ALDH1A1SMN1; SMN2
SCHEMBL13052122 0.82 ACHE (0.66) LOXL2ALDH1A1SMN1; SMN2KDM4ENPC1
SCHEMBL9826363 0.82 SMN1; SMN2 (0.58) CYP4A11CYP4F2ALDH1A1SMN1; SMN2KDM4E
SCHEMBL846524 0.82 SIGMAR1 (0.51) CYP4A11CYP4F2LOXL2ALDH1A1SMN1; SMN2
SCHEMBL5067508 0.81 LOXL2 (0.61) CYP4A11CYP4F2LOXL2ALDH1A1SMN1; SMN2
SCHEMBL5656954 0.81 LTA4H (0.51) CYP4A11CYP4F2LOXL2ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060276433-A1 Hydrazone derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-12-07 US disclosed
EP-1612204-A1 HYDRAZONE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-01-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276433-A1 Hydrazone derivative APP, PRNP, HTT CYP4A11 1959/4885CYP4F2 2825/4885LOXL2 3994/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.